Orchestra BioMed director buys 20,000 shares

David Pacitti, a director of Orchestra BioMed Holdings, Inc. (OBIO), purchased 20,000 shares on November 9, 2026, at $5.00 per share in the issuer’s underwritten public offering.

Available on EDGAR 11/09/2026 - 04:32 PM EST Accepted by SEC EDGAR 11/09/2026 - 04:31 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

David Pacitti, a director of Orchestra BioMed Holdings, Inc. (OBIO), purchased 20,000 shares on November 9, 2026, at $5.00 per share in the issuer’s underwritten public offering. The price was the stated public offering price. His direct holdings after the purchase were 74,750 shares. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Net Buyer: 20,000 shares

Net Buy 1 txn

Insider Pacitti David

Role Director

Bought 20,000 shs ($100K)

Increase in Position 36.5%

Type	Security	Shares	Price	Value
Purchase	Common Stock, par value $0.0001 per share F1	20,000	$5.00	$100K

Holdings After Transaction: Common Stock, par value $0.0001 per share — 74,750 shares (Direct)

Holdings Before and After: Common Stock, par value $0.0001 per share, 54,750 to 74,750 shares (Direct)

Other Insiders: 3 other insiders reported open-market purchases of this stock in the 30 days up to this filing.

Footnotes (1)

1. F1. These shares were purchased in an underwritten public offering of the Issuer at the public offering price of $5.00 per share.

Key Figures

Shares purchased: 20,000 shares Public offering price: $5.00 per share Direct holdings after purchase: 74,750 shares

3 metrics

Shares purchased 20,000 shares November 9, 2026

Public offering price $5.00 per share Price paid for the purchase

Direct holdings after purchase 74,750 shares Following the November 9, 2026 purchase

Key Terms

Common Stock, underwritten public offering, public offering price

3 terms

Common Stock financial

"Common Stock, par value $0.0001 per share"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

underwritten public offering financial

"purchased in an underwritten public offering of the Issuer"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

public offering price financial

"at the public offering price of $5.00 per share"

The public offering price is the amount of money a company charges investors to buy its shares during a new stock sale to the public. It determines how much the company raises and how much each share is worth at the start of trading. For investors, it helps gauge the initial value of the stock and whether it might be a good investment opportunity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many OBIO shares did director David Pacitti purchase, and at what price?

David Pacitti, a director of Orchestra BioMed Holdings, Inc. (OBIO), purchased 20,000 shares at $5.00 per share on November 9, 2026. The purchase was in the issuer’s underwritten public offering at the public offering price. His direct holdings afterward were 74,750 shares; no Rule 10b5-1 plan is reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pacitti David

(Last) (First) (Middle)

C/O ORCHESTRA BIOMED HOLDINGS, INC.

150 UNION SQUARE DRIVE

(Street)

NEW HOPE PENNSYLVANIA 18938

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	11/09/2026		P(1)		20,000	A	$5	74,750	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were purchased in an underwritten public offering of the Issuer at the public offering price of $5.00 per share.

	/s/ Andrew Taylor, Attorney-in-Fact	11/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)